Mark Breidenbach
Stock Analyst at Oppenheimer
(1.74)
# 3,290
Out of 5,182 analysts
48
Total ratings
30.91%
Success rate
1.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.72 | +157.35% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $16.03 | +87.15% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $10.82 | +778.00% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.52 | +352.90% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.50 | +1,892.43% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $8.33 | +2,781.15% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.29 | +6,886.90% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.58 | +171.32% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.93 | +1,558.03% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $3.70 | +305.41% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.70 | +1,392,757.14% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.72
Upside: +157.35%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $16.03
Upside: +87.15%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $10.82
Upside: +778.00%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.52
Upside: +352.90%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.50
Upside: +1,892.43%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $8.33
Upside: +2,781.15%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.29
Upside: +6,886.90%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.58
Upside: +171.32%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.93
Upside: +1,558.03%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.70
Upside: +305.41%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.70
Upside: +1,392,757.14%